分子靶向治疗三阴性乳腺癌无进展 生存期的网状Meta分析

分子靶向治疗三阴性乳腺癌无进展生存期的网状Meta分析

葛龙,李伦刘爱萍张俊华张珺田金徽

兰州大学循证医学中心,兰州大学第一临床医学院;兰州大学第一临床医学院;兰州大学循证医学中心

收稿日期:2016-10-07 修回日期:2016-10-07 出版日期:2016-10-25 发布日期:2016-10-25
基金资助:
]甘肃省循证医学与临床转化重点实验室开放基金；兰州大学中央高校基本科研业务专项资金资助(lzujbky-2015-170;lzujbky-2014-18)

Targeted therapies for progression free survival in treating of triple-negative breast cancer: a network meta-analysis

Evidence-based Medicine Center of Lanzhou University,

Received:2016-10-07 Revised:2016-10-07 Online:2016-10-25 Published:2016-10-25

摘要/Abstract

摘要： 目的：网状Meta分析靶向药物治疗三阴性乳腺癌(TNBC)的无进展生存期（PFS）。方法：系统检索PubMed、EMBASE.com、the Cochrane Central Register of Controlled Trials(CENTRAL)、Web of Science(via ISI Web of Knowledge)、BIOSIS Previews(via ISI Web of Knowledge)和Chemical Abstracts(CA)等数据库，追踪三阴性乳腺癌靶向治疗的系统评价或综述的参考文献，纳入靶向药物治疗三阴性乳腺癌的随机对照试验，由2名研究人员独立提取纳入研究的数据，并评价纳入研究的方法学质量，贝叶斯网状Meta分析采用WinBUGS 1.4软件。结果：共纳入13个随机对照试验，包含2307例患者。纳入的研究方法学质量较高。直接比较的Meta分析结果显示：对比单纯化疗，贝伐单抗联合化疗能改善PFS（HR=0.63，95%CI：0.39～0.90）；其他靶向治疗药物联合化疗在改善PFS差异无统计学意义。间接比较的Meta分析结果显示8种干预方案之间在改善患者PFS上差异均无统计学意义。结论：靶向药物联合化疗治疗三阴性乳腺癌具有一定的疗效，然而证据的样本量不足，尚需要更多设计严谨、大样本的随机对照试验深入研究。

Abstract: Objective: Our network meta-analysis aims to determine which is the best targeted therapies for progression free survival (PFS) in treating of triple-negative breast cancer (TNBC). Methods: Six databases and the references of relative systematic review or meta-analysis were searched to identify randomized controlled trials (RCTs) of containing molecularly targeted agents in the treatment of TNBC. Two reviewers independently extracted related data and assessed the methodological quality of included studies. Bayesian network meta-analysis was conducted using WinBUGS version 1.4 software. Results: A total of 13 RCTs met our inclusion criteria, involved 2307 patients. The methodological quality of included RCTs was good. The results of direct comparisons showed that chemotherapy combination bevacizumab could significantly improve PFS when compared with chemotherapy alone. The results of indirect comparisons presented that there were no significant differences between targeted agents. Conclusions: The targeted agents combined with chemotherapy for TNBC was effective slightly. More RCTs with scientific methods were urgently needed in targeted agents for TNBC.

葛龙,李伦刘爱萍张俊华张珺田金徽. 分子靶向治疗三阴性乳腺癌无进展生存期的网状Meta分析[J]. .

参考文献

[1] Jansen JP, Fleurence R, Devine B, et al. Interpreting Indirect Treatment Comparisons and Network Meta-Analysis for Health-Care Decision Making: Report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: Part 1[J]. Value in Health, 2011, 14(4):417-428.
[2] Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons[J]. Statistics in Medicine, 2004, 23(20):3105-3124.
[3] American Cancer Society. Cancer Facts and Figures 2014. Atlanta, Ga: American Cancer Society, 2014.SAvailable online. Last accessed October 2, 2014.
[4] Bayraktar S,SGl?ck S.MolecularlyStargetedStherapiesSforSmetastaticStriple-negative breast cancer[J]. BreastSCancerSRes Treat,S2013,138(1):21-35.
[5] Cheang MC, Voduc D, Bajdik C, et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype[J]. Clin Cancer Res, 2008,14:1368-1376.
[6] Bauer KR, Brown M, Cress RD, et al. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry[J]. Cancer, 2007,109:1721-1728.
[7] Cleator S,SHeller W,SCoombes RC.Triple-negative breast cancer:StherapeuticSoptions[J].Lancet Oncol,S2007,8(3):235-244.
[8] Brower V. SearchSforSnewStreatmentsSintensifiesSforStriple-negativeSbreastScancer[J]. J NatlSCancerSInst, 2009;101(22):1536-1537.
[9] Clark OAC, Engel T, Paladini L, et al. Targeted Therapy in Triple-Negative Metastatic Breast Cancer (TNBC) - A Systematic Review and Meta-Analysis[J]. Core Evid, 2013, 9(9):1-11.
[10] Bramati A, Girelli S, Torri V, et al. Efficacy of biological agents in metastatic triple-negative breast cancer[J]. Cancer Treat Rev, 2014, 40(5):605-613.
[11] Brufsky A,SValero V,STiangco B,Set al. Second-line bevacizumab-containing therapy in patients with triple-negative breast cancer: subgroup analysis of the RIBBON-2 trial[J].Breast Cancer Res Treat, 2012,133(3):1067-1075.
[12] Brufsky AM,SHurvitz S,SPerez E,Set al. RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer[J].J Clin Oncol, 2011,29(32):4286-4293.
[13] O'Shaughnessy J, Osborne C, Pippen JE, et al.Iniparib plus chemotherapy in metastatic triple-negative breast cancer[J].N Engl J Med, 2011,364(3):205-2014.
[14] Finn RS,SPress MF,SDering J,Set al. Estrogen receptor,Sprogesterone receptor,Shuman epidermal growth factor receptor 2S(HER2), andSepidermal growth factor receptorSexpressionSandSbenefitSfromSlapatinibSin aSrandomizedStrialSofSpaclitaxelSwithSlapatinibSor placeboSasSfirst-lineStreatmentSinSHER2-negativeSorSunknownSmetastaticSbreast cancer[J]. J Clin Oncol,S2009,27(24):3908-3915.
[15] Curigliano G,SPivot X,SCort?s J,Set al.Randomized phase II study of sunitinib versus standard of care for patients with previously treated advanced triple-negative breast cancer[J].Breast, 2013,22(5):650-656.
[16] Tr?dan O, Campone M, Jassem J,Set al.Ixabepilone Alone or With Cetuximab as First-Line Treatment for Advanced/Metastatic Triple-Negative Breast Cancer[J].Clin Breast Cancer, 2015,15(1):8-15.
[17] Carey LA,SRugo HS,SMarcom PK,Set al.TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer[J].J Clin Oncol, 2012,30(21):2615-2623.
[18] Baselga J,SG?mez P,SGreil R,Set al.Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer[J].J Clin Oncol, 2013,31(20):2586-2592.
[19] Baselga J,SSegalla JG,SRoch? H,Set al. Sorafenib in combination with capecitabine: an oral regimen for patients with HER2-negative locally advanced or metastatic breast cancer[J].J Clin Oncol, 2012,30(13):1484-1491.
[20] Bergh J,SBondarenko IM,SLichinitser MR, et al. First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study[J].J Clin Oncol, 2012,30(9):921-929.
[21] Pivot X,SSchneeweiss A,SVerma S,Set al. Efficacy and safety of bevacizumab in combination with docetaxel for the first-line treatment of elderly patients with locally recurrent or metastatic breast cancer: results from AVADO[J]. Eur J Cancer, 2011, 47(16):2387-2395.
[22] Miller K,SWang M,SGralow J,Set al.Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer[J].N Engl J Med, 2007,357(26):2666-2676.
[23] Robert NJ, Di?ras V,SGlaspy J,Set al. RIBBON-1:Srandomized,Sdouble-blind,Splacebo-controlled,Sphase III trialSofSchemotherapySwith or without bevacizumabSforSfirst-lineStreatmentSofShumanSepidermal growth factor receptorS2-negative,SlocallySrecurrentSor metastaticSbreast cancer[J]. J Clin Oncol,S2011,29(10):1252-1260.
[24] O'Shaughnessy J,SSchwartzberg L,SDanso MA, et al.Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer[J].J Clin Oncol,2014,32(34):3840-3847.
[25] 韩华正, 李永安. 三阴性乳腺癌分子靶向治疗的研究进展[J]. 临床肿瘤学杂志, 2012, 17(5):470-474.